Over recent decades, the development of highly sensitive and specific cell-based assays for MOG antibody detection has allowed us to identify a subset of patients with a clinical phenotype distinct from MS and neuromyelitis optica spectrum disorders associated with aquaporin-4 antibodies (AQP4 + NMSOD) [5,6]. Here, AQP4 is linked to myeloid sarcoma.